Pre-Test More than Skin Deep: Examining the Full Impact of Tardive Dyskinesia Pre-Test Which of the following tools would you choose to assess the spectrum of potential consequences associated with TD? A. Abnormal Involuntary Movement Scale (AIMS) B. Global Assessment of Function (GAF) Scale C. Impact-TD D. Rush Dyskineseia Rating Scale (RDRS) E. Unsure TD is reversible in approximately what percentage of patients after withdrawal of a dopamine receptor blocking agent? A. 13% B. 33% C. 53% D. 73% E. Unsure Which of the following is a recommendation in the APA guidelines regarding the treatment of TD? A. Anticholinergics may improve TD symptoms in certain scenarios B. Anti-seizure medications are useful in the treatment of TD C. VMAT-2 inhibitors should not be considered for patients with mild TD D. The VMAT-2 inhibitors deutetrabenazine or valbenazine are preferred over tetrabenazine E. Unsure Which of the following statements regarding VMAT2 inhibitors currently approved for TD is TRUE? A. Both deutetrabenazine and valbenazine require the temporary discontinuation of antipsychotic therapy B. Deutetrabenazine has few dosing options but a long half-life (15–20 hours), allowing q.d. administration C. Dosage adjustments are necessary if patients are on medications that are metabolized by the CYP2D6 and CYP3A4 pathways D. Valbenazine has more dosing options to titrate varying degrees of VMAT2 occupancy but a shorter half-life, requiring b.i.d. administration E. Unsure How confident are you in your ability to assess and measure the functional impact of TD in practice settings? A. Very confident B. Confident C. Somewhat confident D. Not very confident E. Not at all confident How confident are you in your ability to optimally employ VMAT-2 inhibitors FDA-approved to treat TD? A. Very confident B. Confident C. Somewhat confident D. Not very confident E. Not at all confident
